Cel-Sci Corp (CVM) 1.09 $CVM
Cel-Sci's Enrollment Math Doesn't Add up
at The Street - Fri Aug 01, 10:11AM CDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
Business Wire - Fri Aug 01, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled.
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
Business Wire - Wed Jul 30, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the French Agency for the Safety of Health Products has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey.
CEL-SCI Has Been Cleared to Begin Patient Enrollment
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Yesterday morning, CEL-SCI Corporation (NYSE MKT:CVM) announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine.
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
Business Wire - Tue Jul 22, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). The Company expects to enroll patients through three clinical centers in Turkey. Turkey thus becomes the 16th country to participate in the world's largest Phase III head and neck cancer trial.
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
Business Wire - Thu Jul 17, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that Sri Lanka's Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
Business Wire - Tue Jul 15, 7:02AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of Health (NIH). The grant will fund the further development of CEL-SCI's LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints. According to Visiongain, the world rheumatoid arthritis drug market will generate revenues of $38.5 billion in 2017.
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
Business Wire - Fri Jul 11, 8:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, delivered a scientific presentation at the 12th Vaccines Research & Development: All Things Considered Conference in Boston, Massachusetts held on July 9-11, 2014.
CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer Trial into Austria
Business Wire - Tue Jul 08, 7:15AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI's trial which is already active in numerous clinics around the world.
CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jul 01, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of June the Company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled, with 8 in January, 6 in February, and 14 in March. Since the beginning of 2014, the Company has enrolled a total of 82 patients. This compares with 10 patients enrolled in the first half of 2013.
Stock to Watch: CEL-SCI Up 5.1% (CVM)
Comtex SmarTrend(R) - Mon Jun 23, 10:40AM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 5.1% to $1.24 on 1.8x average daily volume. Thus far today, CEL-SCI has traded 919,000 shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's -0.3%) and outperformed the S&P 500 (5.1% to the S&P's -0.2%) during today's trading.
CEL-SCI to Present at the 2014 BIO International Convention
Business Wire - Wed Jun 18, 8:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2014 BIO International Convention on Wednesday, June 25th, at 2:00 p.m. PDT. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California.
Research and Markets: CEL-SCI Corporation - Product Pipeline Review - 2014
Business Wire - Mon Jun 16, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7m7bb4/celsci) has announced the addition of the "CEL-SCI Corporation - Product Pipeline Review - 2014" report to their offering.
CEL-SCI Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 16, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rwrrf3/celsci) has announced the addition of the "CEL-SCI Corporation - Product Pipeline Review - 2014" report to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides brief overview of CEL-SCI Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CEL-SCI Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CEL-SCI Corporation's pipeline products For more information visit http://www.researchandmarkets.com/research/rwrrf3/celsci
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jun 03, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014.
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Business Wire - Mon Jun 02, 8:30AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer.
Hot Stock: CEL-SCI, Shares Gain 8.4% (CVM)
Comtex SmarTrend(R) - Thu May 29, 12:44PM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 8.4% to $1.16 on 1.1x average daily volume. CEL-SCI has traded 936,000 shares thus far today, vs. average volume of 873,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.0%) and outperformed the S&P 500 (8.4% to the S&P's 0.2%) during today's trading.
Global Myocarditis Therapeutics Pipeline Report 2014
M2 - Thu May 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvmqgt/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Novartis AG - CEL-SCI Corporation Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/vv...yocarditis
Cel-Sci's Enrollment Math Doesn't Add up
at The Street - Fri Aug 01, 10:11AM CDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
Business Wire - Fri Aug 01, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled.
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
Business Wire - Wed Jul 30, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the French Agency for the Safety of Health Products has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey.
CEL-SCI Has Been Cleared to Begin Patient Enrollment
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Yesterday morning, CEL-SCI Corporation (NYSE MKT:CVM) announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine.
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
Business Wire - Tue Jul 22, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). The Company expects to enroll patients through three clinical centers in Turkey. Turkey thus becomes the 16th country to participate in the world's largest Phase III head and neck cancer trial.
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
Business Wire - Thu Jul 17, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that Sri Lanka's Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
Business Wire - Tue Jul 15, 7:02AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of Health (NIH). The grant will fund the further development of CEL-SCI's LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints. According to Visiongain, the world rheumatoid arthritis drug market will generate revenues of $38.5 billion in 2017.
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
Business Wire - Fri Jul 11, 8:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, delivered a scientific presentation at the 12th Vaccines Research & Development: All Things Considered Conference in Boston, Massachusetts held on July 9-11, 2014.
CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer Trial into Austria
Business Wire - Tue Jul 08, 7:15AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI's trial which is already active in numerous clinics around the world.
CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jul 01, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of June the Company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled, with 8 in January, 6 in February, and 14 in March. Since the beginning of 2014, the Company has enrolled a total of 82 patients. This compares with 10 patients enrolled in the first half of 2013.
Stock to Watch: CEL-SCI Up 5.1% (CVM)
Comtex SmarTrend(R) - Mon Jun 23, 10:40AM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 5.1% to $1.24 on 1.8x average daily volume. Thus far today, CEL-SCI has traded 919,000 shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's -0.3%) and outperformed the S&P 500 (5.1% to the S&P's -0.2%) during today's trading.
CEL-SCI to Present at the 2014 BIO International Convention
Business Wire - Wed Jun 18, 8:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2014 BIO International Convention on Wednesday, June 25th, at 2:00 p.m. PDT. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California.
Research and Markets: CEL-SCI Corporation - Product Pipeline Review - 2014
Business Wire - Mon Jun 16, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7m7bb4/celsci) has announced the addition of the "CEL-SCI Corporation - Product Pipeline Review - 2014" report to their offering.
CEL-SCI Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 16, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rwrrf3/celsci) has announced the addition of the "CEL-SCI Corporation - Product Pipeline Review - 2014" report to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides brief overview of CEL-SCI Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CEL-SCI Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CEL-SCI Corporation's pipeline products For more information visit http://www.researchandmarkets.com/research/rwrrf3/celsci
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jun 03, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014.
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Business Wire - Mon Jun 02, 8:30AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer.
Hot Stock: CEL-SCI, Shares Gain 8.4% (CVM)
Comtex SmarTrend(R) - Thu May 29, 12:44PM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 8.4% to $1.16 on 1.1x average daily volume. CEL-SCI has traded 936,000 shares thus far today, vs. average volume of 873,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.0%) and outperformed the S&P 500 (8.4% to the S&P's 0.2%) during today's trading.
Global Myocarditis Therapeutics Pipeline Report 2014
M2 - Thu May 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvmqgt/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Novartis AG - CEL-SCI Corporation Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/vv...yocarditis
